Slide 1: MaxCyte Corporate Presentation
® ® ® ® TM is a trademark of MaxCyte, Inc. are registered trademarks of MaxCyte, Inc. in the U.S.A. Driving the Next Generation of Cell-Based Therapies MaxCyte Corporate Presentation NASDAQ: MXCT • LSE: MXCT August 2024
Slide 2: Disclaimer
2 Disclaimer The content of this document (the “Presentation”) has not been approved by an authorized person within the meaning of the Financial Services and Markets Act 2000 (“FSMA”), as amended. Reliance on this document for the purpose of engaging in any investment activity may expose an individu
Slide 3: A Leading Provider of Cell-Engineering Platform Technologies
With 723 platforms in place*, our proprietary technology unlocks the significant potential of advanced therapeutics Leading the growing next-generation cell therapy market and capitalizing on rising demand for non-viral engineering approaches Innovative business model focused on value creation and s
Slide 4: Who We Are - Collaborative, Innovative and Experienced Partner
Who We Are - Collaborative, Innovative and Experienced Partner Impact 28 SPL Partnerships Signed Since 2017 143 Employees* 36+ Field Sales and Application Scientists* Scientific Foundation 1999 2000 Scalable GT Transfection System 2002 FDA Master File 2008 Scalable STx Transfection System 2018 ATx G
Slide 5: ExPERT Platform Addresses Industry Challenges
ExPERT Platform Addresses Industry Challenges MaxCyte technology allows plug and play processes with rapid optimization delivering reproducible outcomes and the ability to seamlessly scale up from pre-IND to the clinic and commercialization Next-generation cell therapy programs have become increasin
Slide 6: Partnering with MaxCyte
Accelerate Product Development Shared Momentum Unparalleled Support Streamlined Regulatory Process Stable Supply Chain Clinically-Validated Platform Partnering with MaxCyte 6 © 2024 MaxCyte, Inc. All Rights Reserved
Slide 7: MaxCyte: Leading Partner for Complex Cellular Engineering
MaxCyte: Leading Partner for Complex Cellular Engineering 28 Strategic Platform Licenses (SPL), including 5 in 2023 and 5 in 2024 1 Commercial Program* 28 Signed SPLs 160+ Programs* Clinical Licenses that are part of our SPLs 16 Programs are currently in clinical development * Cleared INDs or Equiva
Slide 8: Value Creation from SPLs
Value Creation from SPLs Licensing deals include significant development milestones and high-value participation in future commercial success of partners Potential value of pre-commercial (clinical development) milestones from SPLs: ~$2B Sales-based payments upon partner’s product commercialization
Slide 9: Cell Therapy Partner Program Value Schematic
Instruments and Processing Assemblies Milestones Sales-Based Payments Cell Therapy Partner Program Value Schematic Early Clinical: (Phase 1/2) Years 1-3 Mid-6-figure to Low-7-figure milestones 1-3+ instruments + disposables Mid-late Clinical: (Phase 2/3) Years 3-5+ 7-figure milestone per product inc
Slide 10: SPL Partnerships Offer Significant Revenue Upside, Particularly in Commercial
SPL Partnerships Offer Significant Revenue Upside, Particularly in Commercial Higher Value Partnership Value Influencing Factors: • Large indications – greater royalty revenues or early achievement of sales-based milestones • Instrument & consumables – Higher utilization Significant upside in commer
Slide 11: MaxCyte Partnerships – Near and Long-Term Revenue Potential
MaxCyte Partnerships – Near and Long-Term Revenue Potential with Strong Upside in Commercial Opportunity First Wave 1 Approved Partner Program Launched: 2023 SPL Program: Vertex’s Exa-Cel Indications: Sickle Cell Disease Beta-Thalassemia Second Wave 5 Potential Approved Partner Programs Launch Poten
Slide 12: MaxCyte-Enabled Active Clinical Trials
MaxCyte-Enabled Active Clinical Trials 12 00 Allogeneic Autologous Cell Approach: Phase 1 Phase 1/2 Pivotal Commercial Clinical Phase: As of March 2024 / Includes Commercial and Academic Clinical Trials HSCs Other Cell Types APN401 (Invios GmbH) EDIT301: SCD (Editas Med) EDIT301: B-thal Trem-cel (Ed
Slide 13: First MaxCyte-Enabled Therapy is Approved
13 First MaxCyte-Enabled Therapy is Approved CASGEVYTM for Sickle Cell Disease and for Beta-Thalassemia (2023/2024) MaxCyte Enables Next-Generation Cell Therapies Across a Variety of Diseases Gene-Editing Tools used in MaxCyte-Enabled Clinical Trials Indications in Active MaxCyte-Enabled Clinical Tr
Slide 14: The ExPERT Platform Enabling Non-Viral Cell Engineering
The ExPERT Platform Enabling Non-Viral Cell Engineering • Launched in 2019 based on MaxCyte’s proprietary Flow Electroporation® technology and has been optimized for the past 20+ years • Leverages the reversible permeability of the cell membrane in response to an electric charge • Universally delive
Slide 15: MaxCyte Business Model – Drug Discovery Market
MaxCyte Business Model – Drug Discovery Market Drug Discovery Revenue Model Instrument sale (ATx/STx) Single-use disposables (processing assemblies) Razor/Razor Blade Economics DRUG DISCOVERY & DEVELOPMENT - Cells used to Discover / Produce Drug Products Key Applications: Cell-based assays, protein
Slide 16: MaxCyte Business Model – Cell Therapy Market
MaxCyte Business Model – Cell Therapy Market Razor/Razor Blade Economics CELL THERAPY – Cell itself is the Drug Key Applications: Ex-Vivo Engineered Cell Therapies Customer Base: Leading global cell therapy developers and academic translational centers + = 16 Full scale RUO Small/mid-scale RUO Precl
Slide 17: 2023 Summary and 2024 YTD Achievements
2023 Summary and 2024 YTD Achievements • Five SPL partnerships announced in 2023: • Prime Medicine in August, Lyell Immunopharma and Vittoria Biotherapeutics in July, Walking Fish Therapeutics in May and Catamaran Bio in January • Douglas J. Swirsky appointed MaxCyte’s Chief Financial Officer, bring
Slide 18: Thank you! Any questions?
Thank you! Any questions? ir@maxcyte.com 18 © 2024 MaxCyte, Inc. All Rights Reserved
Slide 19: Appendix – Historical Core Business Disclosure
Appendix – Historical Core Business Disclosure 1Q'21 2Q'21 3Q'21 4Q'21 1Q'22 2Q'22 3Q'22 4Q'22 1Q'23 2Q'23 3Q'23 4Q'23 1Q'24 2Q’24 (in $ thousands) Cell Therapy 4,729 4,766 6,226 7,263 7,416 7,688 7,897 7,544 5,975 6,637 4,700 5,518 6,415 6,218 Drug Discovery 1,762 1,838 1,909 2,885 2,167 1,916 1,99